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might thus have been regarded as a
zoonosis in the very first phase but later
has spread in the human population as a
typical anthroponosis and caused the
present pandemic. Similarly, pandemic
strains of influenza developed through an
antigenic shift from avian influenza A
viruses. For some etiologic agents or
their genotypes, both animals and
humans are concurrent reservoirs (hepa-
titis virus E, Norwalk-like calicivirus,
enteropathogenic Escherichia coli,
Pneumocystis, Cryptosporidium, Giar-
dia, and Cyclospora); these diseases
might conditionally be called anthropo-
zoonoses. Other difficulties can occur
with classifying diseases caused by
sporulating bacteria (Clostridium and
Bacillus): Their infective spores survive
in the soil or in other substrata for very
long periods, though they are usually pro-
duced after a vegetative growth in the abi-
otic environment, which can include ani-
mal carcasses. These diseases should
therefore be called sapronoses. For some
other etiologic agents, both animals and
abiotic environment can be the reservoir
(Listeria, Erysipelothrix, Yersinia pseudo-
tuberculosis, Burkholderia pseudomallei,
and Rhodococcus equi), and the diseases
might be, in fact, called saprozoonosis
(not sensu 9 ) in that their source can be
either an animal or an abiotic substrate.
For a concise list of anthropo-, zoo-,
and sapronoses, see the online appendix
available from: URL: http://www.
cdc.gov/ncidod/EID/vol9no3/02-0208-
app.htm.
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Multidrug-Resistant
Shigella dysenteriae
Type 1: Forerunners
of a New Epidemic
Strain in Eastern
India?
To the Editor: Multidrug-resistant
Shigella dysenteriae type 1 caused an
extensive epidemic of shigellosis in east-
ern India in 1984 (1). These strains were,
however, sensitive to nalidixic acid, and
clinicians found excellent results by
using it to treat bacillary dysentery cases.
Subsequently, in 1988 in Tripura, an
eastern Indian state, a similar outbreak of
shigellosis occurred in which the isolated
strains of S. dysenteriae type 1 were even
resistant to nalidixic acid (2). Since then,
few cases of shigellosis have occurred in
this region, and S. dysenteriae type 1
strains are scarcely encountered (3). In
other regions of the world, especially in
Southeast Asia, low-level resistance to
fluoroquinolones in Shigella spp. has
been observed for some time (4,5). 
After a lapse of almost 14 years, clus-
ters of patients with acute bacillary
dysentery were seen at the subdivisional
hospital, Diamond Harbour, in eastern
India. No cases of dysentery had been
reported during the comparable period in
previous years. A total of 1,124 case-
patients were admitted from March
through June 2002. The startling feature
of these infections was their unrespon-
siveness to even the newer fluoro-
quinolones such as norfloxacin and
ciprofloxacin, the drugs often used to
treat shigellosis. Clinicians tried various
antibiotics, mostly in combinations,
without benefit. Clinicians also random-
ly used anti-amoebic drugs without suc-
cess. 
An investigating team collected nine
fresh fecal samples from dysentery
patients admitted to this hospital; 4
(44%) yielded S. dysenteriae type 1 on
culture. For isolation of Shigella spp.,
stool samples were inoculated into
MacConkey agar and Hektoen Enteric
agar (Difco, Detroit, MI), and the charac-
teristic colonies were identified by stan-
dard biochemical methods (6).
Subsequently, serogroups and serotypes
were determined by visual inspection of
slide agglutination tests with commercial
antisera (Denka Seiken, Tokyo).
Antimicrobial susceptibility testing was
performed by an agar diffusion disk
method, as recommended by the
National Committee for Clinical
Laboratory Standards (7). Results
showed that the organisms were resistant
to all commonly used antibiotics, includ-
ing the fluoroquinolones (norfloxacin
and ciprofloxacin) but were sensitive to
ofloxacin. On our advice, the clinicians
used ofloxacin with good results.
A similar outbreak of S. dysenteriae
type 1 occurred in the northern part of
West Bengal in eastern India among tea
garden laborers from April 2002 to May
2002; 1,728 persons were affected
(attack rate of 25.6%). Sixteen persons
died. The isolated S. dysenteriae type 1
strains were found intermediately sensi-
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tive to fluroquinolones with an MIC of 2
µg/mL (K. Sarkar, S. Ghosh, S.K.
Niyogi, S.K. Bhattacharya, pers. com-
mun.). 
This drug-resistant Shiga bacillus is
highly likely to spread further and will
certainly pose a major therapeutic chal-
lenge unless adequate preventive meas-
ures are immediately instituted to contain
its spread. Appropriate awareness pro-
grams for the community and reorienta-
tion training for physicians and other
health personnel would be helpful to pre-
vent further transmission of these resist-
ant organisms. Alternative drugs to treat
drug-resistant cases and an effective vac-
cine are also needed. 
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